Details of the Drug Combination

General Information of Drug Combination (ID: DCY4WQ6)

Drug Combination Name
Fosmidomycin Azithromycin
Indication
Disease Entry Status REF
Malaria Phase 1 [1]
Component Drugs Fosmidomycin   DM7G0EP Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fosmidomycin
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [2]
Fosmidomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium DOXP reductoisomerase (Malaria DXR) TTLH4J3 DXR_PLAFX Binder [6]
------------------------------------------------------------------------------------
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [3]
Bronchitis CA20 Approved [4]
Chancroid N.A. Approved [3]
Mycoplasma pneumoniae pneumonia N.A. Approved [3]
Staphylococcus aureus infection N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Pneumonia caused by chlamydia N.A. Investigative [3]

References

1 ClinicalTrials.gov (NCT01464125) Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults
2 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
3 Azithromycin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
5 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
6 Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7.